Collaborations

Genmab partners to develop product to treat fungal infections

Published in AIDS Weekly, December 15th, 2003

Genmab, A/S, and privately held ACE BioSciences, A/S, will develop an antibody therapeutic product with the potential to treat fungal infections.

The antibody will be directed against a novel target on Aspergillus fumigatus. This fungus can cause life-threatening infections in patients whose immune systems are compromised, for example, cancer patients receiving chemotherapy.

The target discovered by ACE BioSciences is the first in the collaboration between Genmab and ACE BioSciences that covers four commercially promising disease targets in the area of infectious diseases. Under the agreement, ACE BioSciences provides novel commercially...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry